Business Wire18d
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY ... primary endpoints. In the phase IIb trial (NCT05921903 3) a single dose of the vaccine ...
London South East1mon
Positive efficacy data of Arexvy over 3 seasons
The vaccine efficacy is estimated using a Poisson model adjusted by age, region and season. *** Seasonality covariate means the data have ... The trial's primary endpoint was vaccine efficacy ...
FiercePharma18d
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine ... on both of its primary endpoints. In the other study, a single dose of Arexvy provided a ...
GlobalData on MSN1mon
GSK reports positive findings from Phase III RSV vaccine trial
GSK has unveiled positive data from its Phase III AReSVi ... including those at increased risk. The primary endpoint of the ...
Benzinga.com18d
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK's Arexvy shows strong immune response in ... 18-49 may be at risk for RSV due to underlying conditions. The data show that the vaccine has the potential to help protect a broader group of ...
London South East18d
New positive Arexvy data in younger adults at risk
New data for Arexvy, GSK's respiratory ... (n=417), meeting the trial's co-primary endpoints. In the phase IIb trial (NCT05921903[3]) a single dose of the vaccine showed a robust immune response ...
Zacks.com on MSN1mon
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...
Investing1mon
GSK's RSV vaccine shows sustained efficacy over three seasons
PHILADELPHIA - GSK plc (LSE/NYSE: GSK) revealed new data from its phase III trial for the AREXVY ... virus (HSV) vaccine candidate, GSK3943104, after it failed to meet the primary efficacy ...
Pharmabiz17d
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
GSK plc announced new preliminary data for Arexvy (respiratory syncytial ... 60 and above (n=417), meeting the trial’s co-primary endpoints. In the phase IIb trial (NCT059219033) a single dose of the ...
Yahoo Finance18d
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory ... the trial’s co-primary endpoints. In the phase 2b trial, a single dose of the vaccine showed a robust ...
Investing1mon
GSK's RSV vaccine shows sustained efficacy over three seasons
PHILADELPHIA - GSK plc (LSE/NYSE: LON:GSK) revealed new data from its phase III trial for the AREXVY (Respiratory Syncytial ... the herpes simplex virus (HSV) vaccine candidate, GSK3943104, after it ...